Web Results

Mecasermin - Wikipedia


Mecasermin (INN) (trade name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I), which is used for the long-term treatment of growth failure in ...

Mecasermin: Indications, Side Effects, Warnings - Drugs.com


Jan 6, 2017 ... Easy to read patient leaflet for mecasermin. Includes indications, proper use, special instructions, precautions, and possible side effects.

Mecasermin - DrugBank


May 16, 2007 ... Description, Mecasermin contains recombinant-DNA-engineered human insulin- like growth factor-1 (rhIGF-1). IGF-1 consists of 70 amino acids ...



Manufacturer's information about recombinant human insulin-like growth factor-1, marketed under the brand name Increlex (generic name mecasermin).

Increlex (mecasermin) - CenterWatch


Listing for FDA approved drug therapies archives from CenterWatch. ( mecasermin)

Increlex - FDA


INCRELEX® (mecasermin [rDNA origin] injection) number of cases indicative of anaphylaxis requiring hospitalization have been reported. Parents and patients ...

Insulin-Like Growth Factor-1 (IGF-1) Analogues: Mecasermin ... - Aetna


Number: 0711. Policy. Aetna considers mecasermin (Increlex) and mecasermin rinfabate (Iplex)* medically necessary for the treatment of growth failure in ...

Increlex®, mecasermin - OmedaRx

www.omedarx.com/files/Increlex, mecasermin dru126.pdf

Policy No: dru126. Topic: Increlex®, mecasermin. Date of Origin: January 3, 2006 . Committee Approval Date: January 8, 2016. Next Review Date: January 2017.

INCRELEX, INN: mecasermin - European Medicines Agency


INCRELEX (mecasermin) is recombinant human insulin-like growth factor-1 ... Mecasermin was granted orphan status in the EU for “Treatment of growth ...